PD-144418

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H22N2O
Molecular Weight	282.3801
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCN1CCC=C(C1)C2=CC(=NO2)C3=CC=C(C)C=C3

InChI

InChIKey=FOQRKFCLRMMKAT-UHFFFAOYSA-N

InChI=1S/C18H22N2O/c1-3-10-20-11-4-5-16(13-20)18-12-17(19-21-18)15-8-6-14(2)7-9-15/h5-9,12H,3-4,10-11,13H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C18H22N2O
Molecular Weight	282.3801
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25100754 | https://www.ncbi.nlm.nih.gov/pubmed/9144641

PD 144418 oxalate is a remarkably potent and selective sigma1 receptor ligand having potential antipsychotic properties. PD 144418 oxalate displayed an apparent affinity (Ki) of 0.08 nM for sigma1 sites in guinea pig brain membranes and a Ki of 1377 nM for sigma2 sites in rodent neuronal NG108-15 cell membranes. PD 144418 oxalate was classified as sigma1 receptor antagonist based upon several assays, including the ability to attenuate mescaline-induced scratching in mice. PD 144418 oxalate attenuates cocaine-induced hyperactivity in mice. It showed potential antipsychotic activity, but no antidepressant or anxiolytic actions.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sigma opioid receptor 63 Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9144641	Antagonist 2778		0.08 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Psychotic disorder 26 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9144641	Primary		Preclinical	Unknown Approved Use Unknown
Cocaine addiction 28 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25100754	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Mice: the effects of PD 144418 oxalate (1 and 10 mg/kg) on cocaine-stimulated (1, 3 and 10 mg/kg) locomotor activity was evaluated. PD 144418(10 mg/kg) was also tested against haloperidol (0.1, 0.3 and 1 mg/ kg)-induced suppression of locomotor activity. In each study, PD 144418 oxalate was administered 30 min prior to testing, and cocaine or haloperidol was administered 10 min before the 1 hr locomotor activity test. All injections were i.p.

Route of Administration: Intraperitoneal

In Vitro Use Guide

PD 144418 oxalate reversed the NMDA-induced increase in cGMP levels with IC50 value of 4.5 uM in rat cerebella slices.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:29:17 GMT 2023` Edited by `admin` on `Sat Dec 16 17:29:17 GMT 2023`
Record UNII	FV9595VZB7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PD-144418

Code

English

1,2,3,6-TETRAHYDRO-5-(3-(4-METHYLPHENYL)-5-ISOXAZOLYL)-1-PROPYLPYRIDINE

Systematic Name

English

PD144418

Code

English

PYRIDINE, 1,2,3,6-TETRAHYDRO-5-(3-(4-METHYLPHENYL)-5-ISOXAZOLYL)-1-PROPYL-

Systematic Name

English

Code System Code Type Description

CAS

154130-99-1